



NIH AIDS Reagent Program

20301 Century Boulevard
Building 6, Suite 200
Germantown, MD 20874
USA

Phone: 240 686 4740
Fax: 301 515 4015
aidsreagent.org

DATA SHEET

Reagent:	☒ MT-2 Cells
Catalog Number:	237
Lot Number:	150226
Release Category:	A
Provided:	6.30 x 10 ⁶ cells/ml and viability is 87%.
Cell Type:	HTLV-1 transformed human T-cell leukemia cells.
Propagation Medium:	RPMI 1640, 90%; fetal bovine serum, 10%.
Freeze Medium:	RPMI 1640, 70%; fetal bovine serum, 20%; DMSO, 10%.
Growth Characteristics:	Split 1:10 approximately every three days when cells reach a density of 2 x 10 ⁶ /ml. Cells grow in clumpy suspension.
Sterility:	Negative for mycoplasma, bacteria and fungi.
Description:	MT-2 cells were produced by co-culturing normal human cord leukocytes with leukemic T-cells from a patient with adult T-cell leukemia.
Special Characteristics:	MT-2 cells are transformed with and are continuous producers of HTLV-I virions and should be handled accordingly. They have been cloned for maximal cytopathic effects with LAV and cured of mycoplasma by Dr. John Riggs, Virology Laboratory, California Department of Public Health, Berkeley, California.
Recommended Storage:	Liquid nitrogen.

ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL, AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT, FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.

Contributor: Dr. Douglas Richman.

References: Haertle T, Carrera CJ, Wasson DB, Sowers LC, Richman DD, Carson DA. Metabolism and anti-human immunodeficiency virus-1 activity of 2-halo-2', 3'-dideoxyadenosine derivatives. *J Biol Chem* **263**:5870-5875, 1988. [Abstract](#)

Harada S, Koyanagi Y, Yamamoto N. Infection of HTLV-III/LAV in HTLV-I-carrying cells MT-2 and MT-4 and application in a plaque assay. *Science* **229**:563-566, 1985. [Abstract](#)

NOTE: Acknowledgment for publications should read "The following reagent was obtained through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH: MT-2 Cells from Dr. Douglas Richman." Also include the references cited above in any publications.

Last Updated March 14, 2017

ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL, AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT, FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.